CVKD - Cadrenal Therapeutics, Inc. Common Stock Stock Analysis

Stock Taper

SCREENER COMPARE ANY 2 STOCKS

CVKD

CADRENAL THERAPEUTICS, INC. COMMON STOCK

NASDAQ

$1.54

▼ DOWN 1.60% (-0.03)

KEY STATISTICS

Market Cap$5.49 M

52w High$14.64

52w Low$1.49

Dividend Yield—

Frequency—

P/E-0.31

Volume30.01K

Shares Out.3.57M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Quang X. Pham

COMPENSATION 2026

Salary$751,275

Stock Awards$0

Incentive Plan Pay$0

All Other Comp.$14,000

Total$1,909,694

ABOUT

SECTOR

Healthcare

WENT PUBLIC

January 20, 2023

METHOD OF GOING PUBLIC

SPAC

FULL TIME EMPLOYEES

PRICE TARGET

Target High$32.00

Target Low$32.00

Target Median$32.00

Target Consensus$32.00

UPCOMING EARNINGS

DateNov 9, 2026

DayMonday

Rev. Est.—

NOV

MON

SPLIT RECORD

DATE	TYPE	RATIO
2024-08-20	Reverse	1:15

PRICE

$1.54 ▼ DOWN 1.60% (−$0.03)

OVERLAYS

About Cadrenal Therapeutics, Inc. Common Stock

https://www.cadrenal.com ↗

Cadrenal Therapeutics, Inc., founded in 2022 and based in Ponte Vedra, Florida, is a clinical-stage biopharmaceutical company developing Tecarfarin, an orphan drug for preventing thromboembolism in patients with end-stage renal disease and atrial ...

INDUSTRY

Biotechnology

A PRODUCT CADRENAL THERAPEUTICS, INC. COMMON STOCK IS KNOWN FOR

Tecarfarin

Tecarfarin is a Phase 3-ready oral anticoagulant candidate developed as an alternative to warfarin for preventing blood clots in high-risk cardiovascular patients with ESKD or LVADs.